Omisirge is specifically indicated for individuals aged 12 years and older who are planned for umbilical cord blood transplantation following a myeloablative conditioning regimen, such as radiation or chemotherapy.
Stem cell transplantation is a common treatment for blood cancers, which represent about 10% of annual US cancer cases. One source of healthy stem cells is umbilical cord blood.
Before receiving this kind of transplant, patients will generally undergo a course of treatments to remove their own stem cells and prepare the body for new ones, which may weaken the immune system and increase the risk of severe infections.
